Table 3.
Ref. | Phase | n | Treatment | Stage | Post-operative complications (n) | pCR |
Dipetrillo et al[26], 2012 | II | 25 | Induction FOLFOX + BV followed by BV 5 mg/kg, 5-FU 200 mg/m2 daily, oxaliplatin 50 mg/m2 weekly, RT 50.4 Gy in 28 fr. | II-III | Infection (4) | 20% |
Delayed healing (3) | ||||||
Leak/abscess (2) | ||||||
Sterile fluid collection (2) | ||||||
Ischemic colonic reservoir (1) | ||||||
Fistula (1) | ||||||
Nogué et al[27], 2011 | II | 47 | Induction XELOX + BV followed by BV 5 mg/kg, CAPE 825 mg/m2 bid, RT 50.4 Gy in 28 fr. | II-III | Wound infection (10) | 36% |
Intra-abdominal infections (7) | ||||||
Anastomotic leak (5) | ||||||
Stoma complications (2) | ||||||
Other (not specified) (10) | ||||||
Vivaldi et al[28], 2013 | II | 15 | Induction FOLFOXIRI + BV followed by BV 5 mg/kg, CAPE 825 mg/m2 bid or 5-FU 225 mg/m2 daily, RT 50.4 Gy in 28 fr. | II-III | Dehiscence of anastomosis (1) | 38% |
CT: Chemotherapy; CT-RT: Chemo-radiotherapy; BV: Bevacizumab; RT: Radiotherapy; 5-FU: 5-fluorouracil; CAPE: Capecitabine; fr.: Fractions; FOLFOX: 5-FU and oxaliplatin; XELOX: Capecitabine and oxaliplatin; pCR: Pathological complete response.